PF 6741086

Drug Profile

PF 6741086

Alternative Names: PF-06741086; PF-6741086

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
  • Mechanism of Action Antifibrinolytic agents; Blood coagulation factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 06 Dec 2017 Pfizer plans a phase II trial for Haemophilia (SC) (NCT03363321) (EudraCT2017-001255-31)
  • 02 May 2017 PF 6741086 receives Orphan Drug status for Haemophilia A in USA before May 2017 (Pfizer pipeline, May 2017)
  • 08 Mar 2017 Phase-II clinical trials in Haemophilia in Chile (IV) (NCT02974855)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top